Quality of osteoarthritis management and the need for reform in the US

Authors

  • David J. Hunter,

    Corresponding author
    1. University of Sydney, Sydney, New South Wales, Australia
    2. New England Baptist Hospital, Boston, Massachusetts
    • Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia

    Search for more papers by this author
  • Tuhina Neogi,

    1. Boston University Schools of Medicine and Public Health, Boston, Massachusetts
    Search for more papers by this author
  • Marc C. Hochberg

    1. University of Maryland School of Medicine, Baltimore
    Search for more papers by this author
    • Dr. Hochberg has received consultant fees (less than $10,000 each) from Abbott Laboratories, Amgen, AstraZeneca Pharmaceutical Co., Bayer Health Care LLC, BioIberica SA, Bristol-Myers Squibb Company, CombinatoRx, Covidien, Eli Lilly and Company, Endo Pharmaceuticals, GlaxoSmithKline, Hoffman-La Roche, Inc., Merck & Co., Inc., Merck Serono International SA, NiCox SA, Novartis Pharma AG, Pfizer, Inc., Pozen Inc., Rand Corporation, Roche Laboratories Inc., Sanofi Aventis SA, Smith & Nephew, Stryker Biotech, UCB, Inc., and Wyeth Pharmaceuticals, Inc.


Ancillary